E-drug: Therapeutics Letter 43: COX-2 inhibitors update
---------------------------------------------
I would like to bring to your attention the November/December 2001 &
January 2002 issue (#43) of the Therapeutics Letter: "COX-2 inhibitors
update: Do journal publications tell the full story?" that is now
available on the Therapeutics Initiative web-site at
http://www.ti.ubc.ca/pages/letter43.htm
We reviewed all the currently available evidence and concluded that
based on FDA data from the CLASS and VIGOR studies, COX-2 selective
inhibitors are associated with an increased incidence of serious
(life-threatening) adverse events as compared to non-selective NSAIDs.
We found that published versions of the CLASS and VIGOR trials focused
on GI events and failed to report other serious adverse events fully.
One valuable lesson learned is that in the interests of public safety,
serious adverse event rates from all trials must be published.
I invite you to drop by and have a look at this Letter. Please feel free
to forward this message to any of your friends or colleagues that might
be interested in this topic.
We would appreciate receiving your comments on this Therapeutics Letter
and its possible implications in clinical practice.
Best regards,
Ciprian Jauca
Program Coordinator
Therapeutics Initiative - Evidence Based Drug Therapy
University of British Columbia
�
2176 Health Sciences Mall
Vancouver, BC� V6T 1Z3
Canada
�
Phone: +1 (604) 822-0700
GSM Mobile Phone: +1 (604) 722-2075
Fax: +1 (604) 822-0701
Email: jauca@ti.ubc.ca
Web: www.ti.ubc.ca
--
To send a message to E-Drug, write to: e-drug@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: owner-e-drug@usa.healthnet.org
Information and archives: http://www.healthnet.org/programs/edrug.html